TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04188587
Drug: 177 Lu-PSMA-I&T
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were intravenous injected with single dose 2.0-8.0 GBq. The time of the next treatment cycle is determined according to the patient's condition, and it is recommended to treat once every 8-12 weeks.
Study: NCT03959553
Drug: GV1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized peptide from hTERT
Study: NCT03959553
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline
Study: NCT01459081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled by mouth, twice daily, for 5 days
Study: NCT02933866
Drug: DSXS topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical treatment
Study: NCT01173770
Drug: ADC3680B
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADC3680B or Placebo for 7 days
Study: NCT01204242
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room.
Study: NCT03051711
Drug: GBT440
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules which contain GBT440 drug substance in Swedish Orange
Study: NCT00147212
Drug: ET 743
Normalized name: ethanol 0.743 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET-743 administered IV by 24-hr infusion every 3 weeks
Study: NCT04328766
Drug: DWC202005, alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWC202005, as a single dose
Study: NCT04328766
Drug: DWP14012 + DWC202005
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 and DWC202005, as a single dose
Study: NCT04328766
Drug: DWP14012 + DWC202005, after multiple doses of DWP14012
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 and DWC202005, after multiple oral doses of DWP14012 once daily for 12 days
Study: NCT02434978
Drug: IV. PPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients receive 80mg of Esomeprazole iv as a bolus followed by 8mg Esomeprazole per hour for 72 hours.
Study: NCT03978403
Drug: M207 3.8 mg MACAP (two 1.9 mg patches made on a MACAP coater, foil cups)
Approvals — FDA: no, EMA: no, PMDA: no
Description: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a MACAP coater and packaged in foil cups
Study: NCT03978403
Drug: M207 3.8 mg MiniMac (two 1.9 mg patches made on a MiniMac coater, foil cups
Approvals — FDA: no, EMA: no, PMDA: no
Description: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a miniMac coater and packaged in foil pouches
Study: NCT02789033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01817829
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00940160
Drug: QAX576
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00940160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02206659
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00383890
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00618163
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01840371
Drug: Conventional sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol Meperidine : 25 mg IV just before procedure~* IV bolus of 1 mg/kg for sedation induction,~* Infusion of 60 mcg/min/kg for maintenance of sedation~* Additional bolus dose of 10mg as needed for adequate sedation
Study: NCT01840371
Drug: Experimental sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl~* IV bolus of 1 µg/kg for sedation induction~* Additional bolus dose of 0.5 µg/kg as needed for adequate pain control Propofol~* IV bolus of 0.4 mg/kg for sedation induction~* Infusion of 30 µg/min/kg for maintenance of sedation~* Additional bolus dose of 10mg as needed for adequate depth of sedation
Study: NCT02169479
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC, Opicapone
Study: NCT02169479
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLC, Placebo
Study: NCT02169479
Drug: Sinemet® 100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release levodopa/carbidopa 100/25 mg
Study: NCT02456948
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 weeks 200mg/day Minocycline add-on
Study: NCT02456948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 weeks Placebo add-on
Study: NCT00425919
Drug: PPM-204
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01835678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally once a day for 4 weeks
Study: NCT02058095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is \>95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo.~At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 tab of placebo to make a total of 3 tablets of placebo.~At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo.
Study: NCT01502943
Drug: TCM granules placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
Study: NCT01502943
Drug: Chixiangshen Tongxin granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM treatment:~Decoction: Chixiangshen Tongxin granules Herbs: Chishao 10g, Chenxiang 1g, Danggui 10g, Jupi 10g, Yanhusuo 6g, Chuanxiong 6g, Dangshen 10g, Huangqi 6g, Taoren 10g, Honghua 10g Therapeutic Principle:Invigorating Spleen to Replenish Qi and activating blood and dissolving stasis, at least 6 kinds of TCM herbs can be chosen and their dosages be adjusted according to Syndrome Differentiation.~Usage:Once 100ml, twice per day after breakfast and supper.
Study: NCT01502943
Drug: TCM granule placebo plus western basis treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
Study: NCT01502943
Drug: Western basis treatment
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin: 100mg pd. P.O.( patients who have Aspirin resistance or Allergy can replaced with Piece clopidogrel 75mg pd. P.O.) Atorvastatin calcium (Lipitor): 10mg pd. P.O.( patients who have Atorvastatin calcium resistance or Allergy can replaced with Additive amount of pravastatin equal to 10mg Lipitor) Nitroglycerin: sublingual necessary.
Study: NCT01226797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 4 capsules twice daily 12 hours apart with water. Swallow whole.
Study: NCT04101357
Drug: BNT411
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous
Study: NCT04585815
Drug: SEA-TGT
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution in vials
Study: NCT02612857
Drug: IMO-8400 Dose Group 1
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMO-8400 Dose 1 subcutaneous injections once a week for 24 weeks.
Study: NCT02612857
Drug: IMO-8400 Dose Group 2
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMO-8400 Dose 2 subcutaneous injections once a week for 24 weeks.
Study: NCT02612857
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline subcutaneous injections once a week for 24 weeks.
Study: NCT00202488
Drug: H. pylori treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02932943
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
Study: NCT00577460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets identical to Pramipexole ER tablets
Study: NCT00534703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo aliquots will be of the same composition as the investigational medicinal product with the absence of the active ingredient and will be visually indistinguishable from the medicinal product. Placebo is prepared and handled exactly as above in a blinded fashion.
Study: NCT01001208
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate tablets over-encapsulated for blinding
Study: NCT03574649
Drug: 5Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study: NCT03574649
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study: NCT01001208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to methotrexate capsules
Study: NCT01641445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capusules (sugar pills
Study: NCT00551005
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01310049
Drug: LEO 32731
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Part 1 and 2: Oral single dose of oral solution or capsule~* Part 3: Twice daily dose of oral solution or capsule for 7 days
Study: NCT01406678
Drug: isoflurane+sufentanil anesthesia
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
Study: NCT00878995
Drug: Placebo Testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Saline) Testosterone given IM once per week.
Study: NCT00878995
Drug: Testosterone Enanthate 100 MG/ML
Normalized name: testosterone enanthate 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone Enanthate 100mg/ml given once per week IM.
Study: NCT01454284
Drug: LY2605541
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02665117
Drug: Chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone will be administered for 2-3 weeks. Then either KCL or KMgCit will be added to Chlorthalidone and the combination will be taken for 4 months.
Study: NCT01030965
Drug: GSK573719 125mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125mcg once-daily
Study: NCT01345799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04464460
Drug: TAK-671 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-671 placebo-matching intravenous infusion.
Study: NCT00469547
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% ethanol in emollient gel used as a topical male microbicide
Study: NCT01750437
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00447681
Drug: ILV-094
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02254824
Drug: Xuezhikang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang
Study: NCT02924155
Drug: SJP002
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Period 1 (single dose)~   * Day1: Placebo, Topical administered one drop to each eye (Once a day)~  * Day2: SJP002, Topical administered one drops to each eye (Once a day)~  * Day3: SJP002, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])~2. Period 2 (multiple dose) - Day10\~Day23: SJP002, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])
Study: NCT02924155
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Period 1 (single dose)~   * Day1: Placebo, Topical administered one drop to each eye (Once a day)~  * Day2: Placebo, Topical administered one drops to each eye (Once a day)~  * Day3 Placebo, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])~2. Period 2 (multiple dose) - Day10\~Day23: Placebo, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])
Study: NCT03703063
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by intravenous infusion over 30 minutes.
Study: NCT01150747
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 gm once
Study: NCT02744352
Drug: 20ml bolus of 0.5% ropivicaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic
Study: NCT01937390
Drug: Indacterol 300 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhalation powder
Study: NCT01937390
Drug: Indacterol 150 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhalation powder
Study: NCT04183231
Drug: Anti-caries varnish
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical tooth varnish
Study: NCT01874951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo identical in appearance to naltrexone will be given twice daily to all patients assigned to placebo.
Study: NCT00483496
Drug: Ti02 pigmentary 3% alone (formula RV3131A-MV1211)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00483496
Drug: Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00483496
Drug: V0096 CR vehicle (formula RV3131A-MV1197)
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01214122
Drug: AZD9668
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg orally twice daily for 11 days
Study: NCT00025337
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00025337
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00671749
Drug: clindamycin/benzoyl peroxide gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied once daily in the morning
Study: NCT00455624
Drug: Androgen deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to standard medical care
Study: NCT00259610
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: varies
Study: NCT01569152
Drug: MK-8457 100 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8457 100 mg dosed orally BID
Study: NCT01569152
Drug: Dose-Matched Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-matched placebo dosed orally BID
Study: NCT01569152
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX dosed at the stable dose receive upon study entry
Study: NCT01766778
Drug: LAF237 (vildagliptin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 50mg capsule
Study: NCT04359095
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Generic drug distribute by the Colombian Health System. It is used in people with High levels of cholesterol. An action against the main protease (Mpro) of COVID 19 virus has been described, There is evidence suggesting that statins could exert anti Covid 19 action and the infectivity of enveloped viruses
Study: NCT03392571
Drug: NGC-Triple regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine 800 mg/m2; Abraxane (nab-paclitaxel 100 mg/m2; cisplatin 25 mg/m2
Study: NCT03208426
Drug: Clarithromycin (ST14)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Klaricid-XL, clarithromycin, 500mg, bid, for 7 days, (day 8-14)
Study: NCT03208426
Drug: tetracycline (BQ10)
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline (Brand name: Tetracycline Capsule ) 500mg qid for 10 days
Study: NCT00712920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02346201
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two over-encapsulated placebo taken twice a day for 6 months and psychosocial intervention
Study: NCT01681472
Drug: 6R-MTHF (arfolitixorin) 200 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. bolus injection
Study: NCT01681472
Drug: Levoleucovorin 200 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. bolus injection
Study: NCT01681472
Drug: 6R-MTHF (arfolitixorin) 60 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. bolus injection
Study: NCT01681472
Drug: Levoleucovorin 60 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. bolus injection
Study: NCT03015090
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After oral theophylline 200mg per day for one week, blood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2
Study: NCT00677729
Drug: solution contains 1 mg salbutamol plus 3% hypertonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of nebulized study solution containing 1 mg salbutamol plus 3% hypertonic saline every 20 minutes for a total of 3 doses
Study: NCT03273972
Drug: Dosing
Normalized name: oral dosing devices
Approvals — FDA: no, EMA: no, PMDA: no
Description: To be performed at the end of the visit following completion all other study visits
Study: NCT00677729
Drug: solution contains 1 mg salbutamol plus 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of nebulized study solution containing 1 mg salbutamol plus 0.9% saline (NaCl) every 20 minutes for a total of 3 doses
Study: NCT01262911
Drug: SRT2379
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT2379 will be supplied as hard gelatin capsules, with each containing 250mg.
Study: NCT01262911
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
Study: NCT02530359
Drug: Placebo equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo equivalent per mouth
Study: NCT02593851
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral solution will be administered once or twice daily for 7 days.
Study: NCT03651869
Drug: Cigarette 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
Study: NCT03651869
Drug: Cigarette 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
Study: NCT03651869
Drug: Patch 1
Normalized name: COVELET,PATCH 1.5IN X 2IN #0330
Approvals — FDA: no, EMA: no, PMDA: no
Description: A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
Study: NCT03651869
Drug: Patch 2
Normalized name: COVERLET,EYE PATCH 2IN X 3IN
Approvals — FDA: no, EMA: no, PMDA: no
Description: A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
Study: NCT02467244
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: At first visit, after taking detailed history including baseline symptomatology, clinical evaluation, and laboratory investigation, treatment will be started with levothyroxine (50 microgram/day). The dosage of levothyroxine (LT4) will be adjusted (at 4th and 8th week) in an attempt to keep the serum FT4 and TSH concentrations within the normal range. After 12 weeks, all the patients will be followed up, clinical and laboratory tests will be repeated.
Study: NCT04024137
Drug: ZSP1273 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 X 200-mg tablet taken orally
Study: NCT04024137
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets taken orally
Study: NCT04024137
Drug: ZSP1273-400 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 X 200-mg tablet taken orally
Study: NCT04024137
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet taken orally
Study: NCT04024137
Drug: ZSP1273-600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 X 200-mg tablet taken orally
Study: NCT04024137
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets taken orally
Study: NCT04024137
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive matching placebo of ZSP1273
Study: NCT01471522
Drug: Medication
Normalized name: Acne Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
Study: NCT03662568
Drug: RTV
Normalized name: Accu-Chek SmartView Test Strips
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered RTV 100 mg orally three times daily in fed state
Study: NCT02696616
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03318562
Drug: eFT508
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg eFT508 dosed BID for 3 week cycles
Study: NCT02921165
Drug: analgesic mouth rinses (dissolved Aspirin)
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 and Group 2 patients will be prescribed analgesic mouth rinses (dissolved Aspirin) twice daily along with the standard prescription of analgesics and antibiotics.
Study: NCT02921165
Drug: Normal saline rinses.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non Hypertensive patients will be prescribed normal saline rinses twice daily along with the standard prescription of analgesics and antibiotics.
Study: NCT01824758
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: Placebo (NaCl 0.9%, 5 ml), (rocuronium) (0.05mg/kg)
Study: NCT01210001
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching BI 10773 low dose